Sep 4, 2008
FDA staff note deaths in Pfizer bone drug study
By Lisa Richwine
WASHINGTON (Reuters) - Osteoporosis patients given a low dose of an experimental Pfizer Inc pill were more likely to die within five years than others who got a placebo, U.S. drug reviewers said in an analysis released on Thursday.
An increased death rate for women who took the highest dose of the drug Fablyn was not statistically significant in the company study, Food and Drug Administration reviewers said. That means the difference could have been due to chance.
The drug, which the FDA rejected for osteoporosis in 2005, was developed with technology from Ligand Pharmaceuticals Inc.
Read full story from Reuters
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Merck to fund Vioxx settlement in August | 1 hr | DJ -SMD | 1319 |
| MPI Research cutting jobs in Mattawan | 2 hr | Harold | 5 |
| Claims administrator: Interim payments in $4.85... | 3 hr | heraldo | 983 |
| Buffalo - The Next Cleveland? | 4 hr | Wow | 14 |
| Cymbalta leads the way for Lilly (from Feb '07) | 4 hr | edd | 232 |
| Vioxx claimants rush to join $4.85B settlement ... (from Jan '08) | 4 hr | IronLady | 647 |
| Teva Announces Launch of Generic Zoloft (from Nov '06) | 7 hr | KGH Monroe NC | 1113 |
Pisces
Most Popular